logo-loader

FDA grants “priority review” status to AstraZeneca’s breast cancer antibody

Published: 04:22 17 Oct 2019 EDT

AstraZeneca - US authority grants “priority review” status to AstraZeneca’s breast cancer antibody
Rastuzumab deruxtecan is an antibody drug conjugate targeting HER2, a protein found on the surface of some cancer cells in breast cancer patients

Pharma company AstraZeneca PLC (LON:AZN) has announced the US Food and Drug Administration (FDA) granted “priority review” status to its breast cancer antibody.

Rastuzumab deruxtecan is an antibody drug conjugate targeting HER2, a protein found on the surface of some cancer cells in breast cancer patients, and is a potential new medicine to treat metastatic breast cancer.

READ: AstraZeneca gets US clearance for asthma pen

“Trastuzumab deruxtecan has the potential to transform the treatment landscape for patients with HER2-positive metastatic breast cancer who have limited treatment options today,” said José Baselga, executive vice president for oncology research and development.

“This priority review draws on the strength and the consistency of results seen in the Phase I and Phase II trials and is a critical step on the journey to deliver this potential new medicine to patients.”

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

9 hours, 7 minutes ago